Levetiracetam monotherapy for childhood occipital epilepsy of gastaut

Objectives –  The aim of this open label pilot study was to evaluate the efficacy and tolerability of levetiracetam (LEV) as ‘de novo’ monotherapy in children and adolescents with late onset childhood occipital epilepsy–Gastaut type (COE‐G).

[1]  Michael Koutroumanidis,et al.  Benign childhood focal epilepsies: assessment of established and newly recognized syndromes. , 2008, Brain : a journal of neurology.

[2]  N. Fejerman,et al.  Childhood occipital epilepsy of Gastaut: A study of 33 patients , 2008, Epilepsia.

[3]  S. Rothman,et al.  Prolonged Exposure to Levetiracetam Reveals a Presynaptic Effect on Neurotransmission , 2007, Epilepsia.

[4]  M. Ciotti,et al.  Modulation of AMPA Receptors in Cultured Cortical Neurons Induced by the Antiepileptic Drug Levetiracetam , 2007, Epilepsia.

[5]  F. Chiarelli,et al.  Levetiracetam monotherapy for children and adolescents with benign rolandic seizures , 2007, Seizure.

[6]  Jerome Engel,et al.  Report of the ILAE Classification Core Group , 2006, Epilepsia.

[7]  T. Glauser,et al.  Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures , 2006, Neurology.

[8]  Jing-Jane Tsai,et al.  Efficacy and Safety of Levetiracetam (up to 2000 mg/day) in Taiwanese Patients with Refractory Partial Seizures: A Multicenter, Randomized, Double‐blind, Placebo‐controlled Study , 2006, Epilepsia.

[9]  M. Manfredi,et al.  Clinical experience with levetiracetam in idiopathic generalized epilepsy according to different syndrome subtypes. , 2005, Epileptic disorders : international epilepsy journal with videotape.

[10]  L. Lagae,et al.  Clinical experience with levetiracetam in childhood epilepsy: an add-on and mono-therapy trial , 2005, Seizure.

[11]  K. Nocka,et al.  The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Appleton,et al.  Efficacy and tolerability of levetiracetam in children aged 10 years and younger: a clinical experience , 2004, Seizure.

[13]  A. Pelliccia,et al.  Levetiracetam during 1-year follow-up in children, adolescents, and young adults with refractory epilepsy , 2004, Epilepsy Research.

[14]  Josemir W Sander,et al.  Psychiatric adverse events in patients with epilepsy and learning disabilities taking levetiracetam , 2004, Seizure.

[15]  Josemir W Sander,et al.  Psychiatric adverse events during levetiracetam therapy , 2003, Neurology.

[16]  L. Lagae,et al.  Effect of levetiracetam in refractory childhood epilepsy syndromes. , 2003, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[17]  M. Morrell,et al.  The KEEPER™ 1 KEEPER is a trademark of UCB S.A. 1 trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study , 2003, Epilepsy Research.

[18]  B Malgrange,et al.  The anti‐epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA‐ and glycine‐gated currents , 2002, British journal of pharmacology.

[19]  J. Wheless,et al.  Levetiracetam in Refractory Pediatric Epilepsy , 2002, Journal of child neurology.

[20]  N. Fountain,et al.  Efficacy and Safety of Levetiracetam in Children with Partial Seizures: An Open‐label Trial , 2002, Epilepsia.

[21]  D. Ficker,et al.  Levetiracetam: A Different Approach to the Pharmacotherapy of Epilepsy , 2002, The Annals of pharmacotherapy.

[22]  V. Shkryl,et al.  Selective Blockade of N‐Type Calcium Channels by Levetiracetam , 2002, Epilepsia.

[23]  E. Kossoff,et al.  Levetiracetam Psychosis in Children with Epilepsy , 2001, Epilepsia.

[24]  J. Cramer,et al.  A systematic review of the safety profile of levetiracetam: a new antiepileptic drug , 2001, Epilepsy Research.

[25]  D. Margineanu,et al.  Levetiracetam inhibits the high-voltage-activated Ca2+ current in pyramidal neurones of rat hippocampal slices , 2001, Neuroscience Letters.

[26]  C. Panayiotopoulos.  Benign Childhood Epileptic Syndromes With Occipital Spikes: New Classification Proposed by the International League Against Epilepsy , 2000, Journal of child neurology.

[27]  C P Panayiotopoulos,et al.  Early‐Onset Benign Childhood Occipital Seizure Susceptibility Syndrome: A Syndrome to Recognize , 1999, Epilepsia.

[28]  D. Kulling,et al.  Newer antiepileptic drugs: gabapentin, lamotrigine, felbamate, topiramate and fosphenytoin. , 1998, American family physician.

[29]  C. Panayiotopoulos.  Benign childhood partial epilepsies: benign childhood seizure susceptibility syndromes. , 1993, Journal of neurology, neurosurgery, and psychiatry.

[30]  H. Gastaut.  Benign epilepsy of childhood with occipital paroxysms , 1992 .

[31]  H. Gastaut,et al.  A New Type of Epilepsy: Benign Partial Epilepsy of Childhood with Occipital Spike-Waves , 1982, Clinical EEG.